Known targets — ChEMBL curated mechanism
rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Chlortetracycline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.71 |
| ▸ | GAA | P10253 | 3/20 | 0.71 |
| ▸ | LMNA | P02545 | 3/20 | 0.71 |
| ▸ | POLB | P06746 | 3/20 | 0.71 |
| ▸ | THRB | P10828 | 2/20 | 0.71 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.71 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.71 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.71 |
| ▸ | PDE4A | P27815 | 1/20 | 0.71 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.71 |
| ▸ | MEN1 | O00255 | 10/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 10/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 7/20 | 0.70 |
| ▸ | USP2 | O75604 | 5/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.70 |
| ▸ | HPGD | P15428 | 1/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Chlortetracycline SCHEMBL19787489 | 1.00 | MAPT (0.71) | MAPTHSD17B10GAALMNAPOLB | |
| Chlortetracycline SCHEMBL3110 | 1.00 | MAPT (0.71) | MAPTHSD17B10GAALMNAPOLB | |
| Chlortetracycline SCHEMBL5503038 | 1.00 | MAPT (0.71) | MAPTHSD17B10GAALMNAPOLB | |
| Chlortetracycline SCHEMBL10901448 | 1.00 | MAPT (0.71) | MAPTHSD17B10GAALMNAPOLB | |
| Chlortetracycline SCHEMBL12356689 | 1.00 | MAPT (0.71) | MAPTHSD17B10GAALMNAPOLB | |
| Chlortetracycline SCHEMBL13782583 | 1.00 | MAPT (0.71) | MAPTHSD17B10GAALMNAPOLB | |
| Chlortetracycline SCHEMBL13782533 | 1.00 | MAPT (0.71) | MAPTHSD17B10GAALMNAPOLB | |
| Chlortetracycline SCHEMBL16726392 | 1.00 | MAPT (0.71) | MAPTHSD17B10GAALMNAPOLB | |
| Chlortetracycline SCHEMBL20952683 | 1.00 | MAPT (0.71) | MAPTHSD17B10GAALMNAPOLB | |
| Chlortetracycline SCHEMBL3111 | 1.00 | MAPT (0.71) | MAPTHSD17B10GAALMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 670 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4007582-B1 | ANTIBIOTICS IN COMBINATION WITH PHOTODYNAMIC THERAPY FOR USE IN A METHOD OF ENHANCING THE ANTIMICROBIAL ACTION OF SYSTEMICALLY ADMINISTERED ANTIBIOTICS | KOITE HEALTH OY (FI) | 2026-05-20 | — | — | EP | claimed |
| US-20260108455-A1 | DEVICE FOR SUSTAINED CONTROLLED RELEASE OF A THERAPEUTICALLY ACTIVE SUBSTANCE AND USES THEREOF | HYLOMORPH AG (CH) | 2026-04-23 | — | — | US | claimed |
| EP-3955935-B1 | ALKYL-TRIPHENYLPHOSPHONIUM (A-TPP) COMPOUNDS IN COMBINATION THERAPY WITH A GLYCOLYSIS INHIBITOR COMPOUND OR AN OXPHOS INHIBITOR COMPOUND FOR MITOCHONDRIA TARGETING AND FOR USE IN ANTI-CANCER TREATMENTS | LUNELLA BIOTECH INC (CA) | 2026-03-18 | — | — | EP | claimed |
| EP-4554557-B1 | DEVICE FOR SUSTAINED CONTROLLED RELEASE OF A THERAPEUTICALLY ACTIVE SUBSTANCE AND USES THEREOF | HYLOMORPH AG (CH) | 2026-03-11 | — | — | EP | claimed |
| EP-4694929-A1 | METHODS FOR TREATING CORNEAL INJURIES | Lin, Sung-Jan (TW) | 2026-02-18 | — | — | EP | claimed |
| EP-3452124-B1 | HEMOSTATIC DEVICES AND METHODS OF USE | MEDTRONIC INC (US) | 2025-10-08 | — | — | EP | claimed |
| EP-3452123-B1 | HEMOSTATIC DEVICES AND METHODS OF USE | MEDTRONIC INC (US) | 2025-09-24 | — | — | EP | claimed |
| EP-3976197-B1 | THERAPEUTICS AND METHODS FOR PREDICTING AND OVERCOMING ENDOCRINE RESISTANCE IN BREAST CANCER | LUNELLA BIOTECH INC (CA) | 2025-07-16 | — | — | EP | claimed |
| EP-3230500-B1 | METHODS OF ORIENTING MULTIFILAMENT YARN AND MONOFILAMENTS OF POLY-4-HYDROXYBUTYRATE AND COPOLYMERS THEREOF | TEPHA INC (US) | 2025-06-18 | — | — | EP | claimed |
| EP-4554557-A1 | DEVICE FOR SUSTAINED CONTROLLED RELEASE OF A THERAPEUTICALLY ACTIVE SUBSTANCE AND USES THEREOF | Hylomorph AG (CH) | 2025-05-21 | — | — | EP | claimed |
| CN-103849640-B | A kind of oligonucleotide and the method for plasmid cotransformation for the point mutation of intestinal bacteria indispensable gene can be eliminated | NANJING NORMAL UNIVERSITY (CN) | 2016-01-20 | — | — | CN | claimed |
| CN-102703424-B | A kind of method of genome of E.coli point mutation of recombined engineering mediation | NANJING NORMAL UNIVERSITY (CN) | 2015-12-16 | — | — | CN | claimed |
| CN-102653776-B | The method of ethanol is prepared by waste | Hitachi Shipbuilding Corporation (JP) | 2015-11-25 | — | — | CN | claimed |
| CN-104108764-A | Method for restoring antibiotics-polluted wastewater | UNIV SHANDONG | 2014-10-22 | — | — | CN | claimed |
| CN-103849640-A | Method for carrying out point mutations on essential genes on escherichia coli by using co-transformation of oligonucleotide and eliminable plasmids | UNIV NANJING NORMAL | 2014-06-11 | — | — | CN | claimed |
| CN-103328441-A | Process for the manufacture of ajoene derivatives | UNIV DENMARK TECH DTU | 2013-09-25 | — | — | CN | claimed |
| CN-102703424-A | Method for recombination-mediated escherichia coli genome point mutation | UNIV NANJING NORMAL | 2012-10-03 | — | — | CN | claimed |
| CN-102653776-A | Method for preparing ethanol via waste | HITACHI SHIPBUILDING ENG CO | 2012-09-05 | — | — | CN | claimed |
| CN-101027279-A | Synthesis of tetracyclines and analogues thereof | HARVARD COLLEGE (US) | 2007-08-29 | — | — | CN | claimed |
| CN-1890378-A | Stable susceptibility testing for aerobic pathogens | WYETH CORP (US) | 2007-01-03 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260108455-A1 | DEVICE FOR SUSTAINED CONTROLLED RELEASE OF A THERAPEUTICALLY ACTIVE SUBSTANCE AND USES THEREOF | PGF, VEGFA, LDHB | MAPT 3307/4885HSD17B10 1969/4885GAA 486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.